• Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in non-human primate model of Parkinson’s Disease levodopa-induced dyskinesia • Data reinforces Phase 2a pharmacological...
Geneva, Switzerland, 30 April 2013 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Co-Founder and Chief...
• Data reinforces broad therapeutic potential of ADX71441, an oral GABAB receptor Positive Allosteric Modulator • Recent approval of Clinical Trial Application (CTA) to initiate a Phase 1, first–in-man,...
ADX71441, a novel oral small molecule GABA-B receptor positive allosteric modulator, on track to initiate clinical testing in first half of 2013 and to deliver top-line safety, PK and biomarker data by year...
Dipraglurant, an mGlu5 negative allosteric modulator, currently in Phase 2 studies for levodopa-induced dyskinesia is on track for start of Phase 2 studies in rare dystonias in the first half of...
$1 MM grant by The Michael J. Fox Foundation to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia
Geneva, Switzerland, 20 March 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its...
Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs by integrating proprietary functional and structural biology...
• Initiate Phase 2 clinical testing of dipraglurant (mGlu5 NAM) in a rare disease indication • Submit Orphan Drug Application in U.S. and Europe for dipraglurant<br...
Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase 2 clinical testing in the second half of 2013
ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half of 2013
A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis Geneva, Switzerland, 24 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering...
Geneva, Switzerland, 21 March 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex Pharmaceuticals’ new CEO Dr Bharatt Chowrira says he feels a sense of urgency to get on with decision-making at the allosteric modulation-focused Swiss company.
This week’s C&EN cover story is about how X-ray crystal structures of G-protein coupled receptors (GPCRs) help the hunt for new drugs. GPCRs are already a major target for drugs (if not the most popular drug target), but until...
BERLIN, March 14 (APM) - Swiss biotech Addex seems to have turned the corner after the failure of its lead compound during Phase II testing at the end of 2009, with two compounds entering Phase II studies within the next few...
BioCentury Washington Editor Steve Usdin recaps that disease groups provide urgency, a unique perspective on risk and a reminder that patients still demand drugs in an era of healthcare cost-cutting.
Geneva/Brussels – Swiss biotech company Addex Pharmaceuticals S.A. is the first winner of EuropaBio’s new ”Most Innovative European Biotech SME Award”.
The cornerstone of Parkinson’s disease treatment, levodopa, is an effective yet tainted drug - eventually causing side effects as debilitating as the disease it treats.
While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea...
Less than a year after halting its lead program due to liver toxicity signals, Addex Pharmaceuticals has lined up two new sources of financing in two weeks and plans to go forward with a pair of Phase II trials for its new lead...
A Switzerland based pharmaceutical company has turned to a US charity to support its drug development programme as it diversifies fundraising away from a shrinking pool of private investors during the economic slowdown.
The Michael J. Fox Foundation awarded Addex Pharmaceuticals $900,000 to help pay for a Phase II study testing its mGLuR5 modulator ADX48621 for treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), the company...
